Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intraoperative Ketamine on Chronic Pain After Mastectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02729805
Recruitment Status : Unknown
Verified April 2019 by Wong Sau Ching Stanley, The University of Hong Kong.
Recruitment status was:  Active, not recruiting
First Posted : April 6, 2016
Last Update Posted : April 19, 2019
Sponsor:
Information provided by (Responsible Party):
Wong Sau Ching Stanley, The University of Hong Kong

Tracking Information
First Submitted Date  ICMJE June 28, 2015
First Posted Date  ICMJE April 6, 2016
Last Update Posted Date April 19, 2019
Actual Study Start Date  ICMJE August 18, 2015
Estimated Primary Completion Date December 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 31, 2016)
Severity of chronic pain [ Time Frame: At postoperative 3 months ]
Determine the severity using numerical rating scale
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: March 31, 2016)
Incidence of neuropathic pain [ Time Frame: At postoperative 3 months ]
Determine the incidence of neuropathic pain using Identification Pain Questionnaire for Neuropathic Pain (ID-NeP)
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Intraoperative Ketamine on Chronic Pain After Mastectomy
Official Title  ICMJE Effects of Intraoperative Intravenous Ketamine on Chronic Pain After Mastectomy
Brief Summary

Preventive analgesia is when an administered analgesic drug provides reduction in pain beyond its duration of action. This can be used to reduce acute postoperative pain and prevent occurrence of chronic post-surgical pain.

According to the International Association for the Study of Pain (IASP), chronic pain can be defined as pain that persisted beyond the time of normal tissue healing (usually 3 months) and that was not related to other causes. Mastectomy is associated with a high incidence of chronic post-surgical pain. Breast cancer is the most common malignancy affecting females around the world. Many undergo mastectomy as part of curative treatment. However, a significant proportion of patients experience chronic post-surgical pain. This results in significant negative impact on physical, psychological and social wellbeing.

Ketamine is an intravenous anaesthetic drug with analgesic effects. It can be used to treat both acute and chronic pain. A recent meta-analysis of different surgeries showed that patients receiving ketamine had a modest but statistically significant reduction in incidence of chronic post-surgical pain. In a small sample single dose pilot study, patients given low dose intravenous ketamine intraoperatively had a statistically non-significant reduction in incidence of pain around the surgical scar at three months after radical mastectomy. Randomized control trials with larger sample sizes are needed to determine the effectiveness and optimal dosing regime of ketamine for reduction of chronic post-mastectomy pain. It is therefore hypothesized that intravenous ketamine given intraoperatively will reduce the incidence and severity of chronic pain after modified radical mastectomy. A double blind randomized controlled trial comparing placebo group with two different doses of ketamine is proposed.

The mechanism of action of ketamine in reducing pain is complex and multiple. How ketamine can prevent and reduce chronic pain is unknown. Ketamine has been shown to reduce immediate gene expression at site of mechanical injury. Transient Receptor Potential Vanilloid 1 (TRPV1) and Transient Receptor Ankyrin 1 (TRPA1) are receptors shown to mediate acute and chronic pain. Ketamine, shown to affect gene expression, may alter the expression of TRPV1 and TRPA1 via epigenetic mechanisms.

Detailed Description

Procedures Patients will be approached at the preadmission clinic or in the general ward before operation. The analgesic methods will be explained and s/he will be recruited into the study if s/he agrees. The patient will be randomized into one of three groups. The patients in the first group (C) will receive intraoperative morphine, local wound infiltration with local anaesthetic, cyclooxygenase-2 (COX-2) inhibitor post-operatively, and post operative Patient Controlled Analgesia (PCA) morphine. Patients in the second (K1) and third groups (K2) will receive different doses of intraoperative intravenous ketamine in addition to intraoperative morphine, local wound infiltration with local anaesthetic, COX-2 inhibitor, and PCA morphine.

Randomization and blinding Patients recruited for mastectomy will be stratified in randomization. To ensure equal distribution of patients between each type of operation (modified radical mastectomy with axillary dissection and mastectomy with sentinel lymph node without axillary dissection) block randomization will be used. There will be 9 blocks of 15 patients for each type of operation. The allocation order will be selected by a computer generated random sequence.

This is a double blind randomized control trial. Both the patients and the investigators will be blinded to the allocated analgesic modalities: ie the administration of ketamine. Ketamine or normal saline (placebo) will be prepared by clinical staff who will not participate in observation and data analysis.

Data collection

The following data will be collected during the perioperative period:

  • Demographics
  • Time of admission
  • Intraoperative vital signs (blood pressure, heart rate, oxygen saturation)
  • Estimated intraoperative blood loss
  • Volume of intraoperative fluid/blood infusion
  • Duration of anaesthetic or analgesic procedures before surgical procedure
  • Duration of surgical procedures
  • Time from end of surgical procedure to extubation
  • Demands and goods of PCA morphine use
  • Cumulative morphine consumption
  • Vital signs and NRS pain scores at rest and during cough/ipsilateral arm movement upon recovery every hour for 4 hours, and then once every 4 hours for up to 5 days during the time that PCA morphine is used. Afterwards, these data will be collected daily until discharge
  • Dose and frequency of rescues analgesics (Intra muscular injection of morphine) used
  • Side effects of analgesics (pruritus, dizziness, nausea, vomiting, psychomimetic effects etc.)
  • Time to recovery of food intake (fluid, semisolid and solid diet)
  • Time to ambulation (bed rest, sit up, sit out of bed, walk with aid, walk without aid)
  • Surgical and anaesthetic complications, if any (wound infection, urinary retention, etc.)
  • Time to discharge
  • Patient satisfaction upon discharge

The following data would be obtained at 3 and 6 months after surgery:

  • The presence of chronic pain
  • The location of pain
  • Pain severity (Numerical Rating scale (NRS) score): at rest, during cough/movement of the ipsilateral arm
  • Any analgesic consumption
  • Nature of pain: nociceptive, neuropathic
  • Timing of pain occurrence: continuous, related to movement, intermittent.
  • Any abnormal sensation or loss of sensation over operated side.
  • Health related quality of life (HRQOL) data obtained with the Chinese (Hong Kong) version of Short Form-12 version 2 (SF12v2) Health Survey.
  • Patient's psychological condition will be assessed with the Hospital Anxiety and Depression Scale (HADS) questionnaire.
  • Physical examination to check for any brush allodynia and pinprick hyperalgesia

Other data:

  • Survival status at 6 and 12 months after operation
  • Any recurrence of disease
  • Treatment with radiotherapy or chemotherapy
  • If, at certain time point after operation, patient cannot be managed according to the protocol due to any reason such as development of complication, no further data will be collected.

Blood taking for assessment of genetic, epigenetic factors and biomarkers Blood (10mls in tubes with Ethylenediaminetetraacetic acid (EDTA) as preservative) will be taken immediately pre-surgery, immediately post-surgery, one day post-surgery, three days post-surgery, and at 3 and 6-months after surgery.

Data analysis Intention-to-treat will be used. Patients will remain in their initial designated groups for data analysis even if there is a change in surgical or anaesthetic/analgesic management, as long as they have had a laparoscopic incision during the operation.

Statistical methods used:

  • Incidence of chronic post mastectomy pain: Chi-Square test
  • NRS pain scores at 3 and 6 months after surgery, estimated blood loss, duration of anaesthetic, analgesic and surgical procedures, time to extubation, tries and goods of PCA morphine used, cumulative morphine consumption, dose and frequency of rescue analgesic used, time to food intake and ambulation, time to discharge, patient satisfaction: Kruskal-Wallis test
  • Acute NRS pain scores over 48 hours: Expressed as area under the curve (AUC) using the trapezoid rule and compared using Kruskal-Wallis test.
  • Patient demographic data: One way Analysis of Variance (ANOVA) and chi-square test.
  • Intraoperative vital signs, HRQOL, HADS: Repeated measures ANOVA (with Bonferroni correction when appropriate)
  • Side effects and postoperative complications: Chi Square test
  • Binary logistic regression will be used to assess the relationship between development (or non-development) of chronic pain and DNA methylation status of TRPV1 and TRPA1.
  • When a significant result was obtained, t-test or Mann-Whitney test for numerical values and Chi-square test for categorical data will be applied for post hoc pairwise comparisons.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Chronic Pain
Intervention  ICMJE
  • Drug: Saline
    10ml bolus injection of saline followed by intravenous infusion of saline during the operation
    Other Name: Control group
  • Drug: Ketamine 0.5mg/kg
    0.5mg/kg intravenous ketamine injection followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation
    Other Name: Group K1
  • Drug: Ketamine 0.75mg/kg
    0.75mg/kg intravenous ketamine injection followed by 0.5mg/kg/hr intravenous ketamine infusion during the operation
    Other Name: Group K2
Study Arms  ICMJE
  • Placebo Comparator: Saline
    A syringe of 50 ml 0.9% normal saline will be prepared as placebo for infusion and a syringe of 10ml 0.9% normal saline for bolus injection.
    Intervention: Drug: Saline
  • Active Comparator: Ketamine 0.5mg/kg
    A bolus injection of intravenous ketamine at a dose of 0.5mg/kg during anaesthetic induction before skin incision followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation.
    Intervention: Drug: Ketamine 0.5mg/kg
  • Experimental: Ketamine 0.75mg/kg
    A bolus injection of intravenous ketamine at a dose of 0.75mg/kg during anaesthetic induction before skin incision followed by 0.5mg/kg/hr intravenous ketamine infusion during the operation.
    Intervention: Drug: Ketamine 0.75mg/kg
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: March 31, 2016)
135
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 2020
Estimated Primary Completion Date December 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • the American Society of Anesthesiologists adopted physical status classification system (ASA) I-III
  • Age 18-80 years old
  • Scheduled for 1) modified radical mastectomy (including axillary lymph node dissection) and 2) mastectomy with sentinel lymph node (without axillary dissection). These are the common surgical treatments for breast cancer.

Exclusion Criteria:

  • Radical mastectomy, wide local excision or lumpectomy
  • Known allergy to opioids, local anaesthetic drugs, non-steroidal anti-inflammatory drugs (NSAIDS) including COX-2 inhibitors
  • History of chronic pain
  • Alcohol or drug abuse
  • Impaired renal function, defined as preoperative serum creatinine level over 120 micromol/L
  • Pre-existing neurological or muscular disorders
  • Psychiatric illness
  • Impaired or retarded mental state
  • Not self ambulatory before operation
  • Difficulties in using patient controlled analgesia (PCA)
  • Pregnancy
  • Local infection
  • Patient refusal
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Hong Kong
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02729805
Other Study ID Numbers  ICMJE UW15-079
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Wong Sau Ching Stanley, The University of Hong Kong
Study Sponsor  ICMJE The University of Hong Kong
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Stanley SC Wong, MBBS The University of Hong Kong
PRS Account The University of Hong Kong
Verification Date April 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP